A University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse model can dramatically improve heart function and extend survival in several inherited forms of arrhythmogenic cardiomyopathy (ACM). The research suggests that a single gene therapy might someday help a wide range of ACM patients, regardless of the specific mutation they carry. The study was published on January 26, 2026 in Circulation: Heart Failure.
This article was originally published on MedicalXpress.com
